TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02024763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
Study: NCT01729325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preventive Narrative Exposure Therapy
Description: During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
Study: NCT04129853

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberlegs Xleg
Description: Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberlegs Xleg
Description: Sit to stand, Stair Climbing, Slope walking, L-test, Hallway walking with the current vs. cyberlegs xleg and cyberlegs vs power knee
Study: NCT03616925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin Matrix kit
Description: Platelet Rich Fibrin Matrix kit was used to procure platelet rich fibrin matrix using centrifugation machine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical open flap debridement
Description: only surgical open flap debridement was done without use of Platelet Rich Fibrin Matrix kit
Study: NCT02471833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 20mg
Description: Participants will be given 20 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg
Description: Participants will be given 40 mg of telmisartan to be taken orally once a day before bedtime, for a duration of 8 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given placebo to be taken orally once a day before bedtime, for a duration of 8 months.
Study: NCT01171105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5213
Description: oral solution, multiple ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD5213
Study: NCT01535950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFG316

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
Study: NCT00549614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acipimox
Description: capsule, 250 mg, 4 times daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule, 250 mg, 4 times daily for 28 days
Study: NCT01698333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551
Description: Applied twice daily for 2 weeks
Study: NCT01392339

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
Study: NCT04168918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychological Intervention
Description: There will be 6 sessions covering 6 topics (Understanding mental disorders, Self-stigma, Social support, Substance use and mental illness, Self-help strategies, Available mental health services). Each session will begin with welcoming, reviewing what was done in the last session and home assignments (where applicable), question-guided discussion, lecture, group sharing and home assignment
Study: NCT04244292

Intervention type: OTHER
Group type: OTHER
Intervention: Videolaryngoscopy
Description: Patient will be intubated by using videolaryngoscope
Study: NCT00984217

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation 64-70Gy (2.0 Gy/day, 5 days/week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 2.5 mg/Kg IV, weekly during RT. 6-7 weeks
Study: NCT00003553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HLA Matched Peripheral BLood Stem Cells
Description: Cell Product
Study: NCT00807235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized lucinactant
Description: Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized lucinactant
Description: Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
Study: NCT02841930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ActionHealth NYC
Description: care coordination, covered preventive services, and standardized costs for ambulatory care
Study: NCT02954068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Oxytocin + IM placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IM Oxytocin + IV placebo
Study: NCT00865969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Study: NCT00561951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 8mg tablets OD for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Corresponding placebo tablets OD for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fesoterodine fumarate
Description: 4mg tablets OD for 12 weeks
Study: NCT01329965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)
Description: LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)
Description: LPS or placebo (saline-salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
Study: NCT03295110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionalities of the Lili Smart Solution activated
Description: Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.

Intervention type: OTHER
Group type: OTHER
Intervention: Functionalities of the Lili Smart Solution non activated
Description: Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
Study: NCT02466633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-hospital cardiac monitoring method
Description: Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
Study: NCT04229251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Mindfulness-based Intervention
Description: The iMBI starts with psychoeducation about ADHD and defining mindfulness. Participants were then encouraged to discuss their experience of living with ADHD via a series of guided questions. Upon orientated to the program, the participants will be introduced to various topics of mindfulness and ADHD, as well as a wide range of in-session online mindfulness exercises. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session. Downloadable audio tracks for offline practices will be provided to the participants. Participants are expected to spend around 15 to 30 minutes each day to complete the weekly iMBI assignment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Online Introductory Psychology Program
Description: The online introductory psychology program is a mass online open course program, providing comprehensive overview about psychology as an academic discipline. Each week, participants will be presented with approximately 2-hours pre-recorded lecture. Offline assignments that correspond to each week's theme will be assigned to participants at the end of each session.Downloadable handouts for revision will be provided to the participants. Participants are encouraged to spend around 15 to 30 minutes each day to complete the weekly assignment.
Study: NCT04065178

Intervention type: BEHAVIORAL
Intervention: Level of activity
Description: Inpatients will be asked if they are willing to wear a heart rate tracking fitness watch during their stay. They will be asked quality of life questions on a questionnaire that will take approximately 30 minutes to answer at admission and discharge. At the end of the study they will return the Fitbit Charge 2 to the study coordinator or their nurse.~Your rehabilitation plan of care will not change in any other way.
Study: NCT02624310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa (L-DOPS)
Description: Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa (L-DOPS)
Description: Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02895451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended behavioral intervention
Description: The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
Study: NCT02876198

Intervention type: DEVICE
Intervention: Gonioscopy
Description: Study of the trabecular structure by gonioscopy
Study: NCT02767713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
Study: NCT04667897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 601 1.25mg
Description: Solution for injection (intravitreal use)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizuman 0.5 mg
Description: Solution for injection (intravitreal use)
Study: NCT00368992

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT00658099

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation

Intervention type: DRUG
Intervention: insulin NPH
Description: Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
Study: NCT03756246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza Vaccine
Description: The appropriate quadrivalent influenza vaccine for the give year will be given to subjects.
Study: NCT02668185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NK3R antagonist - AZD4901
Description: Neurokinin 3 receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03418337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexilansoprazole (Dexilant 60 mg)
Description: evaluate the response rate (symptom free) during the 8-week PPI therapy for atypical GERD between dexlansoprazole group and lansoprazole group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole (Takepron OD 30 mg)
Description: lansoprazole group
Study: NCT02926625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic follow-up
Description: Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.~HEW advice and procedures~* Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick~* Children who are getting worse should come back immediately or at any time for a re-assessment~* All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.~* HEW should fill out a loose child assessment form~* If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditional follow-up
Description: Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
Study: NCT02730741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lcr restituo® sachet
Description: symptomatic treatment of diarrhoea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lcr restituo® sachet
Description: symptomatic treatment of diarrhoea

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01704924

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Device will be applied at end of procedure over closed incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Dressing
Description: Dressing applied as Standard of Care
Study: NCT02513745

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive Cataract Suite (Verion + ORA)
Description: Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
Study: NCT04130386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants receiving MI

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: e-education
Description: Participants receiving e-education
Study: NCT03013582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amnion Tendon Wrapping
Description: Tendon is wrapped with the allograft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Tenolysis
Description: Surgical release of peritendinous scarred tissue

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgical Tenolysis
Description: Surgical release of peritendinous scarred tissue
Study: NCT04289766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: These individuals will receive the conventional intervention including the routine rehabilitation therapy like active and passive ROMs, stretching, strengthening of upper limb, balance improvement exercises. Time duration is of 40 minute 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Muscle Vibration (120Hz)
Description: These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Muscle Vibration (60Hz)
Description: These individuals will receive conventional therapy along with Focal Muscle Vibration applied to the hyper toned muscles (Bicep Brachialis and Extensor Carpi Radialis). Evaluation at baseline and after the end session (Total 24 session). i.e. 3 sessions/week for 8 weeks.
Study: NCT03595839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fistulotomy
Description: The fistula track is laid open after complete probing till the internal opening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fistulotomy
Description: The fistula track is laid open after complete probing till the internal opening

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Marsupialization
Description: The laid open track will be marsupialized using interrupted absorbable sutures
Study: NCT06382025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: showing cartoons -storybook
Description: A goal-oriented 8-9 minutes animation cartoon that is informative and educational had been developed, and pediatric surgery patients had been asked to watch this animation during preoperative period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: showing cartoons - standard
Description: standard
Study: NCT01800825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This will be an identical placebo comparator made of starch.
Study: NCT01211522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
Study: NCT03876782

Intervention type: DIAGNOSTIC_TEST
Intervention: IOLMaster
Description: IOL power calculation will be done with IOLMaster

Intervention type: DIAGNOSTIC_TEST
Intervention: Verion
Description: IOL power calculation will be done with Verion
Study: NCT04103385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE (Reconnecting to Internal Sensations and Experiences)
Description: The overarching goal of RISE is to increase interoception by reconnecting people with their internal sensations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RISE (Reconnecting to Individual Strength and Energy)
Description: Aims to reduce life stressors and improve physical health